Response of low HER2-expressing ovarian carcinosarcoma to trastuzumab deruxtecan, a case report
1Section of Gynecologic Oncology, Women's Health Institute, Cleveland Clinic, A-81, 9500 Euclid Ave., Cleveland, OH 44195, USA.
Gynecologic Oncology Reports
|December 21, 2023
Abstract:
•Treatment options are limited for recurrent ovarian carcinosarcoma (OCS).•A patient with HER2 1 + IHC and negative FISH amplification was treated with trastuzumab deruxtecan.•A durable partial response was achieved, suggesting a possible treatment option for OCS patients with HER2 expression.


